The interaction between menin and histone-lysine N-methyltransferase 2A (KMT2A) is a critical dependency for KMT2A- or nucleophosmin 1 (NPM1)–altered leukemias and an emerging opportunity for therapeutic development. JNJ-75276617 (bleximenib) is a novel, orally bioavailable, potent, and selective protein-protein interaction inhibitor of the binding between menin and KMT2A. In KMT2A-rearranged (KMT2A-r) and NPM1-mutant (NPM1c) acute myeloid leukemia (AML) cells, JNJ-75276617 inhibited the association of the menin-KMT2A complex with chromatin at target gene promoters, resulting in reduced expression of several menin-KMT2A target genes, including MEIS1 and FLT3. JNJ-75276617 displayed potent antiproliferative activity across several AML and acute lymphoblastic leukemia (ALL) cell lines and patient samples harboring KMT2A or NPM1 alterations in vitro. In xenograft models of AML and ALL, JNJ-75276617 reduced leukemic burden and provided a significant dose-dependent survival benefit accompanied by expression changes of menin-KMT2A target genes. JNJ-75276617 demonstrated synergistic effects with gilteritinib in vitro in AML cells harboring KMT2A-r. JNJ-75276617 further exhibited synergistic effects with venetoclax and azacitidine in AML cells bearing KMT2A-r in vitro, and significantly increased survival in mice. Interestingly, JNJ-75276617 showed potent antiproliferative activity in cell lines engineered with recently discovered mutations (MEN1M327I or MEN1T349M) that developed in patients refractory to the menin-KMT2A inhibitor revumenib. A cocrystal structure of menin in complex with JNJ-75276617 indicates a unique binding mode distinct from other menin-KMT2A inhibitors, including revumenib. JNJ-75276617 is being clinically investigated for acute leukemias harboring KMT2A or NPM1 alterations, as a monotherapy for relapsed/refractory acute leukemia (NCT04811560), or in combination with AML-directed therapies (NCT05453903).
In the search for first-in-class NIK inhibitors for multiple myeloma, we discovered an azaindoline hit class generated from a biochemical NIK autophosphorylation high-throughput screening assay whi...
Poly(ADP-ribose) glycohydrolase (PARG) is the principal enzyme responsible for the degradation of poly(ADP-ribose) chains and has emerged as a promising therapeutic target in oncology within the DNA damage response (DDR) field. Although several reversible PARG inhibitors have recently entered clinical development, covalent inhibition of PARG has not previously been described. Herein, we report the discovery and optimization of the first covalent PARG inhibitors. Guided by structural analysis of the PARG catalytic domain, electrophilic warheads were incorporated into reversible quinazolinedione-based inhibitors to enable selective engagement of Cys872, a residue located within the catalytic pocket. While unsaturated ketone and hydrazide warheads enabled covalent inhibition of PARG, incorporation of a bicyclo[1.1.0]butane (BCB) hydrazide warhead led to the discovery of FORX-175, combining potent biochemical and cellular activity, reduced electrophile reactivity, and improved covalent-labeling selectivity. To the best of our knowledge, this work represents the first application of a BCB hydrazide warhead for selective covalent cysteine targeting. Building on these findings, a hybrid design strategy combining structural elements of the covalent quinazolinedione series with those of a reversible PARG inhibitor series led to the discovery of FORX-425, a covalent quinoline inhibitor bearing an underexplored BCB-carboxamide warhead. FORX-425 displayed potent biochemical inhibition, efficient covalent engagement, and nanomolar cellular activity in PARG-sensitive cancer cell lines. Collectively, these studies establish covalent inhibition as a viable strategy for PARG modulation, identify Cys872 as a tractable site for selective covalent targeting, and further demonstrate the potential of BCB-derived warheads for cysteine-directed drug discovery.
Protein-DNA interfaces are central to genome maintenance but remain challenging targets for small-molecule discovery because they are often broad, polar, solvent exposed, and lack classical druggable pockets. Here, we establish a structure-guided strategy to chemically target such interfaces by combining fragment-based identification of DNA-mimetic binders with covalent capture of a proximal nucleophilic residue. Using the ssDNA-binding groove of RAD52 as a representative model system, an X-ray fragment screen identified carboxylate-containing fragments that recapitulate key phosphate-backbone interactions of ssDNA within the conserved DNA-binding groove. Structural analysis revealed a recurrent 2:1 fragment-binding mode that enabled fragment linking and preorganization, yielding reversible inhibitors with nanomolar biochemical activity. Subsequent exploitation of C64, located adjacent to the bound ligand, converted this reversible scaffold into potent covalent inhibitors. Optimization led to the identification of FORX-864, a beyond-rule-of-5 covalent RAD52 chemical probe with low-nanomolar ssDNA-displacement activity, efficient covalent target engagement, favorable in vitro properties, and submicromolar inhibition of RAD52-dependent single-strand annealing in cells. This work provides a chemical strategy for targeting DNA-binding proteins through DNA-mimetic fragment
Protein-DNA interfaces are central to genome maintenance but remain challenging targets for small-molecule discovery because they are often broad, polar, solvent exposed, and lack classical druggable pockets. Here, we establish a structure-guided strategy to chemically target such interfaces by combining fragment-based identification of DNA-mimetic binders with covalent capture of a proximal nucleophilic residue. Using the ssDNA-binding groove of RAD52 as a representative model system, an X-ray fragment screen identified carboxylate-containing fragments that recapitulate key phosphate-backbone interactions of ssDNA within the conserved DNA-binding groove. Structural analysis revealed a recurrent 2:1 fragment-binding mode that enabled fragment linking and preorganization, yielding reversible inhibitors with nanomolar biochemical activity. Subsequent exploitation of C64, located adjacent to the bound ligand, converted this reversible scaffold into potent covalent inhibitors. Optimization led to the identification of FORX-864, a beyond-rule-of-5 covalent RAD52 chemical probe with low-nanomolar ssDNA-displacement activity, efficient covalent target engagement, favorable in vitro properties, and submicromolar inhibition of RAD52-dependent single-strand annealing in cells. This work provides a chemical strategy for targeting DNA-binding proteins through DNA-mimetic fragment